Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Phase II trial to evaluate immune-related biomarkers for pathological response in stage II-III HER2-positive breast cancer receiving neoadjuvant chemotherapy with subsequent randomization to multi-epitope HER2 vaccine versus placebo in patients with residu
Chumsri, Saranya , Bruggeman, Sarah, Ruddy, Kathryn J. , Northfelt, Donald W. , Advani, Pooja , Moreno‐Aspitia, Alvaro , Knutson, Keith L. , Norton, Nadine , Hillman, David W. , Ernst, Brenda , Sideras, Kostandinos , Goetz, Matthew P. , Knutson, Keith L.

Mayo Clinic

Journal of Clinical Oncology | June 6, 2022 | Volume: 40 | Issue: 16_suppl | Pages: TPS610-TPS610

10.1200/jco.2022.40.16_suppl.tps610 Get It

TPS610 Background: Several studies demonstrated worsening disease-free survival in patients who failed to achieve complete pathological response after neoadjuvant chemotherapy (NAC), particularly in HER2-positive (HER2+) breast cancer. Despite the recent approval of trastuzumab emtansine (T-DM1) in patients with residual disease after NAC approximately 12% of patients still develop recurrent and metastatic disease. TPIV100 is a multi-epitope vaccine that includes a pool of 4 degenerate HER2-derived HLA-DR epitopes, which activate CD4 helper T cells, admixed with GM-CSF. In our previous phase I trial this vaccine was shown to be safe in combination with trastuzumab in stage II-III HER2+ breast cancer after completion of standard of care chemotherapy. Furthermore, this vaccine also generated robust long-lasting T-cell immune responses and antibody immunity against HER2. Methods: This trial is a multi-center, randomized, placebo-controlled, phase II trial of TPIV100 in combination with T-DM1 in stage II-III HER2+ breast cancer patients with residual disease after NAC. This trial is currently opened through the ACCRU consortium. Eligible patients include those with stage II-III HER2+ with residual disease, in the breast and/or lymph nodes, after trastuzumab ± pertuzumab-based NAC, with ECOG PS ≤ 2 and adequate organ function. Patients with baseline left ventricular ejection fraction < 50%, history of trastuzumab-related cardiac toxicity, myocardial infarction or stroke < 6 months, history of congestive heart failure, autoimmune disease, immunocompromised patients with known HIV or those on chronic steroid, hypersensitivity to GM-CSF, and other active malignancy < 3 years are excluded. TPIV100 or placebo, in combination with GM-CSF, will be given concurrently with T-DM1. To ensure that TPIV100 in combination with T-DM1 is safe, there is a run-in phase with 20 patients treated with the combination. If there is no significant dose-limiting toxicity observed in the run-in phase, the trial will be expanded to the randomized phase II portion, which will include 240 patients. Eligible patients will be randomized in a 2:1 fashion with ER/PR as a stratification factor. The primary endpoint is invasive disease-free survival, and the secondary endpoint includes immunogenicity of TPIV100 as assessed by IFN-g ELIspot analysis. Correlative studies include assessment of helper T-cell response distribution (including Th1, Th2, Th17, Tfh), HER2-specific antibody immunity, and HLA genotype. Currently, 20 patients in the run-in phase have been enrolled. Enrollment to the randomized phase II portion is expected to begin in March 2022. Clinical trial information: NCT04197687.
ARST2031: A study to compare early use of vinorelbine and maintenance therapy for patients with high risk rhabdomyosarcoma.
Shern, John, Rudzinski, Erin R. , Skapek, Stephen X. , Rodeberg, David A. , Shenoy, Archana , Maianski, Irit, Maxa, Kim, Fricke, Lindsey, Su, Zhong, Harrison, Douglas J. , Venkatramani, Rajkumar , Allen‐Rhoades, Wendy , Mascarenhas, Leo , Xue, Wei, Donaldson, Sarah S. , Casey, Dana L. , Lautz, Timothy B. , Yedururi, Sireesha , Crompton, Brian D.

Mayo Clinic

Journal of Clinical Oncology | June 6, 2022 | Volume: 40 | Issue: 16_suppl | Pages: TPS11591-TPS11591

10.1200/jco.2022.40.16_suppl.tps11591 Get It

TPS11591 Background: Patients with high-risk rhabdomyosarcoma (HR-RMS) continue to have poor outcomes with 3-year event free survival (EFS) rates of 30% or less despite chemotherapy dose intensification on recent cooperative group RMS trials. Vinorelbine (VINO) has demonstrated clinical activity in RMS patients with relapsed/refractory disease and shown to provide a survival benefit when given with oral cyclophosphamide as maintenance chemotherapy for a select group of patients that achieved first complete remission. Methods: ARST2031 is a randomized Phase 3 trial with the primary aim to compare event-free survival (EFS) of patients with HR-RMS treated with vincristine, dactinomycin and cyclophosphamide (VAC) followed by maintenance with vinorelbine and oral cyclophosphamide (VINO-CPO) or vinorelbine, dactinomycin and cyclophosphamide (VINO-AC) followed by maintenance with VINO-CPO. Patients are stratified by histology and randomly assigned to VAC followed by VINO-CPO maintenance or VINO-AC followed by VINO-CPO maintenance. To be eligible, patients must be ≤ 50 years of age at the time of enrollment with newly diagnosed RMS except adult-type pleomorphic, based upon institutional histopathologic classification. All patients must have Stage 4 disease and patients diagnosed with embryonal RMS (ERMS) must be ≥ 10 years of age. Patients with malignant cytology in cerebrospinal fluid, intra-parenchymal brain metastases, or diffuse leptomeningeal disease are excluded. The study was activated on September 13, 2021 and is anticipated to enroll approximately 4 patients per month. The planned sample size is 100 patients, with approximately 50 patients randomized to each arm. Safety and feasibility of VINO-AC will be assessed in the first 8 patients prior to randomization. The study will have power of 0.8 to detect a hazard ratio of 0.61 (74 events in total) when the one-sided Type I error rate is 0.10, with 30 months of accrual and 2 years of follow-up. The hazard ratio of 0.61 was determined by assuming piecewise exponential distributions and specifying the 2-year EFS of 46% vs. 28% and long-term EFS of 32% vs. 16%, based on prior outcome data. Biospecimens will be collected and banked for future use. Clinical trial information: NCT04994132.
Safety and efficacy of etigilimab in combination with nivolumab in select recurrent/advanced solid tumors.
Hamid, Omid , Merriam, Priscilla , Seetharam, ­Mahesh , Vaishampayan, Ulka N. , Weroha, Saravut J., Krishnan, Suba, George, Angela , Vaishampayan, Ulka , McKean, Meredith Ann , Dumbrava, Ecaterina E. , Mettu, Niharika B , Call, Justin , Kapoun, Ann M. , Lucas, Jennifer

Mayo Clinic

Journal of Clinical Oncology | June 6, 2022 | Volume: 40 | Issue: 16_suppl | Pages: 2651-2651

10.1200/jco.2022.40.16_suppl.2651 Get It

2651 Background: Etigilimab (etig), a humanized IgG1 monoclonal antibody, blocks TIGIT interaction with PVR (poliovirus receptor) and inhibits downstream signalling with target cell killing. Etig +/- nivolumab (nivo) showed acceptable safety and preliminary activity in a FIH Phase 1a/b study in solid tumors. ACTIVATE, an open-label Phase 1b/2 basket study is evaluating further efficacy, safety, tolerability and PK/PD of etig+nivo. This is a preliminary efficacy and safety analysis from ACTIVATE. Methods: Subjects with advanced/metastatic solid tumors without curative/standard of care therapies are given IV etig+nivo Q2W until disease progression or intolerable toxicity. Six open cohorts are enrolling in parallel: endometrial cancer (post-front-line platinum), endometrial cancer (2-3 prior lines), PD-L1+ checkpoint-inhibitor-naïve (CPI-n) cervical cancer, rare cancers (germ cell tumor (GCT), sarcoma, uveal melanoma), ovarian cancer (post-front-line platinum) and TMB-h/MSS, (TMB >10mut/mb) tumors. Tumor assessments are done every 8 weeks following baseline scan. Primary endpoint is investigator-assessed ORR by RECIST 1.1. Secondary endpoints include duration of response and safety. Results: Of 27 efficacy-evaluable subjects enrolled in the 6 open cohorts with minimum 1 staging scan or radiological/clinical progression at data cut-off of 02/10/22, 12 had clinical benefit with 1 complete response (CR), 2 partial responses (PRs) and 9 stable diseases (SDs) and 15 had radiological/clinical progressive disease (PD), with an overall response rate (ORR) of 11% and disease control rate (DCR) of 44%. Conclusions: Etig+nivo is safe and well tolerated with no new safety signals. Early efficacy was noted in cervical cancer (1CR, 1PR and 1SD) and uveal melanoma (3 SDs >20 weeks). Encouraging activity was also noted in ovarian cancer and post-CPI treated TMB-H/MSS NSCLC. These early data support continued evaluation of the combination of etig+nivo. Clinical activity was notable as below. Clinical trial information: NCT04761198. [Table: see text]
A phase 1a dose-escalation study of PY314, a TREM2 (Triggering Receptor Expressed on Macrophages 2) targeting monoclonal antibody.
Patnaik, Amita , Tan, Winston , Jahchan, Nadine S. , Pierce, Kristen J. , Li, Yunfeng , Reyno, Len, Chamberlain, Marc C. , Hamilton, Erika , Winer, Ira Seth , Hubbard, Joleen M. , Schenk, Erin L. , Sonbol, Mohamad Bassam , Pierce, Kristen

Mayo Clinic

Journal of Clinical Oncology | June 6, 2022 | Volume: 40 | Issue: 16_suppl | Pages: 2648-2648

10.1200/jco.2022.40.16_suppl.2648 Get It

2648 Background: To characterize the safety and tolerability of PY314, an immunosuppressive macrophage depleting antibody, as a single agent and in combination with pembrolizumab in subjects with advanced refractory solid tumors including subject’s refractory to checkpoint inhibitors if approved for that indication. Methods: Two were evaluated in subjects with advanced solid tumors, single agent PY314 and PY314 in combination with 200 mg of pembrolizumab using a 3+3 dose escalation study design. Dosing was intravenous and administered once every 3-weeks, a defined cycle. Disease assessment by RECIST 1.1 was performed every 6 weeks. Each stratum included 4 dose levels of PY314 (1, 3, 10, and 20 mg/kg). Pharmacokinetics were evaluated at specified time points. Archival tumor tissue was analyzed for TREM2 expression by immunohistochemistry. Based on preclinical evaluation of TREM2 expression, HR+ HER2- and triple negative breast cancer, colorectal cancer, renal cell cancer, non-small cell lung cancer and gynecologic cancers were studied. Results: 28 subjects (median age 60 years [range 26-76], 22 females and 6 ) with an ECOG PS <2 were enrolled and all, but one was (1 subject withdrew consent after dosing). 15 subjects were treated with single agent PY314 and 13 were treated with the combination. No infusion-related reactions, dose limiting toxicities, suspected unexpected serious adverse reactions or high-grade treatment related adverse events (TRAEs) that resulted in treatment discontinuance was seen. 12 subjects experienced at least one TRAE, and in all but one subject, these were low grade. One subject experienced a treatment-related immune system disorder. serious adverse events, all unrelated to treatment. TREM2 expression in archival tumor ranged from 0.0-20%. PY314 pharmacokinetics were linear, dose proportional, unaffected by concomitant pembrolizumab and with a half-life of 8-9 days. Best radiographic response was stable disease seen in 11 subjects (39.3%) ranging in duration from 9-42 weeks. 6 subjects with stable disease have progressed and 5 remain on treatment. Conclusions: PY314 was well tolerated and has an excellent safety profile both as a single agent and in combination with pembrolizumab. A recommended dose for expansion was derived and enrollment in five prespecified cancers is ongoing. Clinical trial information: 04691375.
Sinonasal Mucosal Melanoma: Role of Tumor Proliferative Indices and Pathological Factors in Survival
Guo, Ruifeng , Jenkins, Sarah M. , Johnson, Brian J. , Reed, Katelyn A. , Kroneman, Trynda, Reed, Katelyn, Choby, Garret , Johnson, Brian Jake , Guo, Ruifeng , Choby, Garret

Mayo Clinic

The Laryngoscope | June 6, 2022 | Volume: 132 | Issue: 12 | Pages: 2350-2358

10.1002/lary.30240 | PMID 35661370 Get It

Objective The objective of this study is to determine the association of proliferation indices and pathologic biomarkers on overall and recurrence/metastasis‐free survival (OS and RMFS) in patients with sinonasal mucosal melanoma (SNMM) and to assess the genetic mutational landscape of SNMM. Methods This is a retrospective cohort study of 45 SNMM patients without neoadjuvant therapy who underwent surgical therapy with curative intent and had tumor tissue available for histopathologic review, molecular analysis, and genetic mutational assessment. The OS and RMFS were assessed for associations with numerous tumor and patient‐related factors. Results Among proliferative indices, higher Ki67 and mitotic rates were associated with worsened OS and RMFS (Ki67: p = 0.0007 and p < 0.0001; mitotic rate: p = 0.005 and p = 0.0009, respectively). The presence of brisk tumor‐infiltrating lymphocytes (TILs) was associated with improved RMFS ( p = 0.007) and the presence of lymphovascular invasion was associated with worsened OS and RMFS ( p = 0.02 and p = 0.04, respectively). Patients with amelanotic tumors were more likely to have higher T‐stage ( p = 0.046), less likely to have brisk TILs ( p = 0.02) and had worsened RMFS ( p = 0.03). Patients on immunotherapy with tumor Ki67 < 40% had better 3‐year OS compared to those with higher Ki67 index ( p = 0.004). Actionable genetic mutations such as BRAF V600E are rare and present in only 1 of 20 patients tested. Conclusion In SNMM patients, pathologic and proliferation markers such as Ki67, mitotic rate and brisk TILs are associated with survival and may be considered in future staging systems. Clinical response to immunotherapy appears to correlate with the Ki67 index. Given the distinct genetic profile of SNMM, targeted therapies against the MAPK kinase pathway have limited utility. Level of Evidence 3 Laryngoscope , 132:2350–2358, 2022
Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up
Martin, Thomas G. , Usmani, Saad Z. , Berdeja, Jesús G. , Agha, Mounzer , Cohen, Adam D. , Hari, Parameswaran , Avigan, David , Deol, Abhinav , Htut, Myo , Lesokhin, Alexander M. , Munshi, Nikhil C. , O’Donnell, Elizabeth , Stewart, A. Keith , Schecter, Jordan M. , Goldberg, Jenna D., Jackson, Carolyn C. , Yeh, Tzu‐Min, Banerjee, Arnob , Allred, Alicia J., Zudaire, Enrique, Deraedt, William , Olyslager, Yunsi, Zhou, Changwei, Pacaud, Lida , Lin, Yi , Jakubowiak, Andrzej , Lin, Yi , Jagannath, Sundar , Lesokhin, Alexander M , Cohen, Adam D , Hari, Parameswaran , Berdeja, Jesús G , Usmani, Saad , Goldberg, Jenna D., Madduri, Deepu , Jakubowiak, Andrzej , Jagannath, Sundar

Mayo Clinic

Journal of Clinical Oncology | June 4, 2022 | Volume: 41 | Issue: 6 | Pages: 1265-1274

10.1200/jco.22.00842 | PMID 35658469 Get It

PURPOSE CARTITUDE-1, a phase Ib/II study evaluating the safety and efficacy of ciltacabtagene autoleucel (cilta-cel) in heavily pretreated patients with relapsed/refractory multiple myeloma, yielded early, deep, and durable responses at 12 months. Here, we present updated results 2 years after last patient in (median follow-up [MFU] approximately 28 months), including analyses of high-risk patient subgroups. METHODS Eligible patients had relapsed/refractory multiple myeloma, had received ≥ 3 prior lines of therapy or were double refractory to a proteasome inhibitor and immunomodulatory drug and had received prior proteasome inhibitor, immunomodulatory drug, and anti-CD38 therapy. Patients received a single cilta-cel infusion 5-7 days after lymphodepletion. Responses were assessed by an independent review committee. RESULTS At a MFU of 27.7 months (N = 97), the overall response rate was 97.9% (95% CI, 92.7 to 99.7); 82.5% (95% CI, 73.4 to 89.4) of patients achieved a stringent complete response. Median duration of response was not estimable. Median progression-free survival (PFS) and overall survival (OS) were not reached; 27-month PFS and OS rates were 54.9% (95% CI, 44.0 to 64.6) and 70.4% (95% CI, 60.1 to 78.6), respectively. Overall response rates were high across all subgroups (95.1%-100%). Duration of response, PFS, and/or OS were shorter in patients with high-risk cytogenetics, International Staging System stage III, high tumor burden, or plasmacytomas. The safety profile was manageable with no new cilta-cel–related cytokine release syndrome and one new case of parkinsonism (day 914 after cilta-cel) since the last report. CONCLUSION At approximately 28 months MFU, patients treated with cilta-cel maintained deep and durable responses, observed in both standard and high-risk subgroups. The risk/benefit profile of cilta-cel remained favorable with longer follow-up.
Multi‐disciplinary collaborative consensus guidance statement on the assessment and treatment of cardiovascular complications in patients with post‐acute sequelae of SARS‐CoV‐2 infection (PASC)
Barry, John T., Bartels, Matthew N. , Fleming, Talya K. , McCauley, Mark , Neal, Jacqueline D., Pillarisetti, Jayasree , Sampsel, Sarah , Terzic, Carmen M., Tosto, Jenna, Fleming, Talya K , Sampsel, Sarah , Verduzco-Gutierrez, Monica , Whiteson, Jonathan H. , Azola, Alba Miranda , Blitshteyn, Svetlana , Silver, Julie K. , Verduzco‐Gutierrez, Monica , Putrino, David F.

Mayo Clinic

PM&R | June 3, 2022 | Volume: 14 | Issue: 7 | Pages: 855-878

10.1002/pmrj.12859 | PMID 35657351 Get It

Facilitators and Barriers to the Implementation of New Critical Care Practices during COVID-19: A Multicenter Qualitative Study using the Consolidated Framework for Implementation Research (CFIR)
Silver, Santana , Jones, Kayla Christine , Redmond, Sarah , George, Emily , Zornes, Sarah, Leppin, Aaron L. , Harmon, Lori, Kumar, Vishakha K. , Kordik, Christina, Barwise, Amelia , Dong, Yue , Walkey, Allan J. , Drainoni, Mari‐Lynn

Mayo Clinic

No container title available | June 3, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1510788/v2 Get It

Abstract Background The COVID-19 pandemic produced unprecedented demands and rapidly changing evidence and practices within critical care settings. The purpose of this study was to identify factors and strategies that hindered and facilitated effective implementation of new critical care practices and policies in response to the pandemic. Methods We used a cross-sectional, qualitative study design to conduct semi-structured in-depth interviews with critical care leaders across the United States. The interviews were audio-taped and professionally transcribed verbatim. Guided by the Consolidated Framework for Implementation Research (CFIR), three qualitative researchers used rapid analysis methods to develop relevant codes and identify salient themes. Results: Among the 17 hospitals that agreed to participate in this study, 31 clinical leaders were interviewed. The CFIR-driven rapid analysis of the interview transcripts generated 12 major themes, which included six implementation facilitators (i.e., factors that promoted the implementation of new critical care practices) and six implementation barriers (i.e., factors that hindered the implementation of new critical care practices). These themes spanned the five CFIR domains (Intervention Characteristics, Outer Setting, Inner Setting, Characteristics of Individuals, and Process) and 11 distinct CFIR constructs. Salient facilitators to implementation efforts included staff resilience, commitment, and innovation, which were supported through collaborative feedback and decision-making mechanisms between leadership and frontline staff. Major identified barriers included lack of access to reliable and transferable information, available resources, uncollaborative leadership and communication styles. Conclusions: Through applying the CFIR to organize and synthesize our qualitative data, this study revealed important insights into implementation determinants that influenced the uptake of new critical care practices during COVID-19. As the pandemic continues to burden critical care units, clinical leaders should consider emulating the effective change management strategies identified. The cultivation of streamlined, engaging, and collaborative leadership and communication mechanisms not only supported implementation of new care practices across sites, but it also helped reduce salient implementation barriers, particularly resource and staffing shortages. Future critical care implementation studies should seek to capitalize on identified facilitators and reduce barriers.
Impact of Low Dose Maltodextrin/Citrulline Loading on the Severity and Duration of Stress Induced Hyperglycemia in Cardiac Surgery
Espinosa, Jairo, Baxter, Jacob , Jose, Joslyn, Khalil, Sarah I. , Dash, Alok, Pratt, Jerry W.

Mayo Clinic

No container title available | May 31, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1680450/v1 Get It

Abstract INTRODUCTION: Postoperative stress induced insulin resistance, and the resulting glycemic variability, is clearly associated with complication rates in cardiac surgery. Despite this, there is a paucity of data regarding the duration of stress induced hyperglycemia in cardiac surgery as well as the impact of specific strategies for carbohydrate loading in cardiac surgery patients. Prior work in colorectal and bariatric surgery has shown a significant reduction in glycemic events with the use of a low dose maltodextrin and citrulline loading strategy, but there is no data that the commonly recommended 50 gram supplements provides any impact on stress induced postoperative hyperglycemia. The aim of this study was to compare standard of care (SOC group) versus a three dose, 25 gram dose carbohydrate loading strategy (CL group) on the duration and severity of postoperative glycemic variability in both diabetic and non-diabetic cardiac surgery patients.METHODS: We compared CABG/AVR/MVR retrospective patients who received standard of care (SOC) to a prospective set of patients who were carbohydrate loaded (CL) with 3 preoperative doses of 25g maltodextrin/3g citrulline (G.E.D.TM, SOF Health, LLC).RESULTS: 152 patients total were included (SOC n=80, CL n= 72). 66 patients were diabetic. In both non-diabetic and diabetic patient populations, there was a statistically significant reduction in glycemic variability in G.E.D. groups for non- diabetics (27% reduction) and diabetics (40% reduction). The glycemic variability on POD 2 was not statistically different between treatment groups in non-diabetics (G.E.D. 25.2% vs SOC 24.7%) but approached significance in diabetics (G.E.D. 24.7% vs SOC 32.9%e). CONCLUSION: These are the first data demonstrating the reduction in post operative stress induced glycemic variability in cardiac surgery using a low dose carbohydrate loading regimen which includes the amino acid citrulline. The impact of surgical stress on glycemic variability appears to resolve by POD#2 in non-diabetics but may persist longer in diabetic patients. These data represent the first information regarding the benefits of a specific strategy for carbohydrate loading to reduces the stress induced component of post operative hyperglycemia in cardiac surgery.
0457 Development and utility of a mobile health application integrated with the electronic heath record for treatment of chronic insomnia disorder
Kolla, Bhanuprakash , Luedke, Tabitha, McColley, Samantha , Phillips, Sarah , Smith, J.M. , Boudreau, Nancy , Morgenthaler, Timothy I. , Kolla, Bhanu Prakash , Anderson, Sandra , Luedke, Tabitha Crystal, Smith, Justin, Boudreau, Nancy, Harper, Sarah

Mayo Clinic

Sleep | May 31, 2022 | Volume: 45 | Issue: Supplement_1 | Pages: A202-A203

10.1093/sleep/zsac079.454 Get It

Abstract Introduction Cognitive behavior therapy for insomnia (CBT-I), a first-line therapy for patients with chronic insomnia disorder (ChID), is underutilized due to reduced access to trained providers and other barriers. We developed an interactive care plan (ICP) combining individual aspects of CBT-I. This ICP, which integrates with the electronic health record (EHR), is designed to deliver personalized and scalable CBT-I to patients with ChID. We report data from initial implementation and evaluation of a ChID ICP deployed at a tertiary sleep medicine clinic. Methods The ICP was developed following patient and provider interviews and focus groups. Patients diagnosed with ChID were offered enrollment and engaged in the ICP through an app. The ICP has embedded logic that may escalate care or offer an exit from the program, depending upon the patient’s response to questions. Key variables ascertained from the patient included sleep efficiency (SE), sleep timing and the Insomnia Severity Index (ISI), and how satisfied they were with their progress (Likert scale). We also measured In Basket messaging related to use of the ICP. Results A total of 222 patients [57% female, age=56.4±15.9 years (average ±SD), 92.7% white] were enrolled in the initial 120 days of ICP implementation. Most referrals were initiated by physicians or advanced practitioners (77.9%). ISI at initiation was 15±5.18 and SE was 74.55±16.65%. Patients spent 35.9±26.25 days engaging with the ICP. The ISI score at 28 days was 12.89±4.98 and SE was 78.9±13.4% with both showing significant improvement from baseline (p=0.013; p=0.002; respectively). Self-rated satisfaction with progress did not significantly correlate with actual improvement in ISI or SE (p&gt;0.05). The ICP generated 3.89±2.3 In Basket messages per patient. Conclusion Patients who actively engaged with the ICP showed significant improvements in insomnia severity and sleep efficiency. While a majority of the patients were neutral towards the ICP and only a small minority expressed dissatisfaction, these data indicate that the ICP will have clinical utility in busy sleep medicine practices with reduced access to behavioral sleep specialists. Support (If Any)